Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

This open-label, non-randomized, first-in-human Phase 1 study involves two stages:

In the Dose-Escalation Stage, ascending dose cohorts will be treated in 2 periods until the
maximum tolerated dose is identified. In Period 1, subjects will receive 2 doses of IGN002
administered weekly. In Period 2, subjects will receive up to 24 additional doses of IGN002
administered weekly in three 8-week cycles. Subjects that have not progressed following the
treatment period will be followed for another 6 months.

In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the identified
maximum tolerated dose administered weekly in three 8-week cycles. Subjects that have not
progressed following the treatment period will be followed for another 6 months.

Inclusion Criteria:

- Documented history of immunohistochemistry (IHC)-confirmed CD20-positive (with no
subsequent history of CD20-negativity) B-cell, NHL, including diffuse large B cell
(DLBCL), mantle cell, marginal zone, lymphoplasmacytic, follicular, transformed
follicular, or primary mediastinal B cell lymphoma

- Refractory disease, having failed available therapies

- Measurable disease

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Life expectancy > 3 months

- Adequate organ function

Exclusion Criteria:

- Treatment with an approved or investigational chemotherapy drug within 28 days of Day
1

- Treatment with an approved or investigational anti-CD20 drug within 28 days of Day 1

- Treatment with an approved or investigational biologic drug that does not target CD20
within 90 days of Day 1

- Radiation therapy within 4 weeks of Day 1